Please assess the completion status of the following clinical trial:

Trial Title: Investigating the Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adults in the following risk groups: physicians, nurses, respiratory therapists, microbiology laboratory personnel working at UCSF Benioff Children's Hospital Oakland or the University of Massachusetts Medical School as well as medical students attending accredited U.S. medical schools~* Able to comprehend and follow all required study procedures~* In good health as determined by a brief medical history~* For females of child bearing age a negative urine pregnancy test will be required~Exclusion Criteria:~* Are not in the risk groups summarized above~* Have not given or are unable to give written informed consent to participate in the study~* Females of child bearing potential who are pregnant, or planning on becoming pregnant during the study period.~* Persons with a past history of having Guillain-Barré Syndrome (GBS), or a family history of GBS in a parent or sibling.~* Persons with presence or suspected presence of serious chronic disease including but not limited to: chronic cardiac disease, autoimmune disease, diabetes, hepatitis B/C, HIV, progressive neurological disease or seizure, leukemia, lymphomas, or neoplasm.~* Have participated in any other investigational drug or received any other vaccine within the last 30 days.~* Received a dose of a meningococcal serogroups A, C, Y, W conjugate vaccine within the previous 30 days or wish to receive a dose of this vaccine during the six month study period.~* Have a history of anaphylactic shock, asthma, urticaria or other allergic reaction after previous dose of Trumenba~* Have experienced fever (oral temperature above 38.0°C) within the past 3 days or are suffering from a present acute infectious disease~* Are planning to leave the area of the study site before the end of the study period~* Have obesity (BMI higher than 33); or 11.~* With any condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Open Label: MenB-FHbp (Type: EXPERIMENTAL): Trumenba Meningococcal Group B Vaccine (Wyeth/Pfizer Pharmaceuticals)

Based on this trial design, predict the completion outcome and termination type (if applicable).